Skip to main content
. 2020 Jun 5:doaa054. doi: 10.1093/dote/doaa054

Fig. 3.

Fig. 3

Distribution of oncological therapy available for esophageal cancers across centers from round 1 and 2 of the survey during the COVID-19 pandemic. (A) Esophageal adenocarcinoma. (B) Esophageal squamous cell carcinoma. (C) Overall changes to treatment strategies in esophagogastric cancer management to cope with the COVID-19 pandemic.